Drugs

, Volume 65, Supplement 1, pp 1–6 | Cite as

Historical Perspective of Gastric Acid Inhibition

Review Article

Abstract

The inhibition of gastric secretion has been a therapeutic objective for decades. A variety of pharmacologic and non-pharmacologic approaches have been proposed throughout history. Among the non-pharmacologic proposals, gastric surgery was widely used until effective drugs were available. Initially antacids and later anti-cholinergics, H2 blockers and proton pump inhibitors took the predominant position. Finally, Helicobacter pylori eradication has been the milestone for the cure of peptic ulcers.

Keywords

Esomeprazole Reflux Oesophagitis Rabeprazole Nizatidine Truncal Vagotomy 

References

  1. 1.
    Cheli R. Gastric secretion. New York: Raven Press, 1986Google Scholar
  2. 2.
    Díaz-Rubio M. Historia de la úlcera. Madrid: You and Us, 1987Google Scholar
  3. 3.
    Pajares García JM, Pajares Villarroya R, Gisbert JP. Úlcera péptica: cambios conceptuales y manejo clínico en 85 años (1918–2003). Rev Esp Enf Diges 2003; 95 (Suppl.): 31–47Google Scholar
  4. 4.
    Winkelstein A. Peptic esophagitis: New clinical entity. J Am Med Ass 1935; 104: 906–9CrossRefGoogle Scholar
  5. 5.
    Rey E, Díaz-Rubio M. Enfermedad por reflujo gastroesofágico: un siglo de historia. Rev Esp Enf Diges 2003; 95 (Special Issue): 18–24Google Scholar
  6. 6.
    Barrett NR. Chronic peptic ulcer of the esophagus and “esophagitis”. Brit J Surg 38; 150: 175–82Google Scholar
  7. 7.
    Allison PR. Reflux esophagitis, sliding hiatal hernia and the anatomy of repair. Surg Gynecol Obstet 1951; 92: 419–31PubMedGoogle Scholar
  8. 8.
    Díaz-Rubio M. Uso de los antiácidos en gastroenterología. In: Díaz-Rubio M, editor. Antiácidos en los 80. Madrid: P & B Editors, 1987Google Scholar
  9. 9.
    Solís Herruzo JA, Díaz-Rubio García M. Nuestra experiencia con la cápsula de Heidelberg en la exploración de la función secretora gástrica. Rev Esp Enf Diges 1970; 30 (Pt 2): 157–78Google Scholar
  10. 10.
    Díaz-Rubio M. Reflujo gastroesofágico. ¿Una enfermedad esofágica o gástrica? Anal Acad Nac Med 1998; 115: 759–80Google Scholar
  11. 11.
    García Albarrán J, Ruíz de León A, Fernández Remis E, et al. Reflujo gastroesofágico. Valoración del tratamiento con ranitidina mediante monitorización continua de pH ambulatoria. In: Díaz-Rubio M, editor. Avances en gastroenterología, vol. 4. Madrid: ARAN, 1987; pp. 43–50Google Scholar
  12. 12.
    Ruíz de León A, Sevilla C, Pérez de la Serna J, et al. Simultaneous two-level esophageal 24-hour pH monitoring in patients with mild and severe esophagitis. Does probe position influence results of esophageal monitoring? Dig Dis Sci 1995; 40: 1423–7Google Scholar
  13. 13.
    Black JW, Duncan WAM, Durant GJ, et al. Definition and antagonism of histamine H2 receptors. Nature 1972; 236: 385–90PubMedCrossRefGoogle Scholar
  14. 14.
    Dobrilla G. Antagonisti dei recettori H2 dell’istamina. Verona: Cortina International, 1986Google Scholar
  15. 15.
    Díaz-Rubio M. Obstacles to maintenance therapy in peptic ulcer. Res Clin Forums 1988; 10: 63–9Google Scholar
  16. 16.
    Díaz-Rubio M. Tratamiento preventivo de las recidivas ulcerosas. In: Díaz-Rubio M, editor. Enfermedad ulcerosa péptica. Madrid: ENE, 1987; 131–40Google Scholar
  17. 17.
    Taxonera Samsó C, Díaz-Rubio M. El problema de los pacientes resistentes. In: Díaz-Rubio M, editor. Enfermedad ulcerosa péptica. Madrid: ENE, 1987; 149–58Google Scholar
  18. 18.
    Ganser AL, Forte JG. K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochem Biophys Acta 1973; 307: 169–80PubMedCrossRefGoogle Scholar
  19. 19.
    Modlin IM. From Prout to the proton pump. Konstanz: Schnetztor-Verlag GmbH, 1995Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Medical Pathology, Gastroenterology Service‘San Carlos’ Clinical University Hospital, Complutense UniversityMadridSpain

Personalised recommendations